Completed PHASE3 INTERVENTIONAL 2-arm NCT01018485

The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor

Double-Blind, Randomized, Controlled, Cross-over Comparison of Efficacy and Safety of Botulinum Toxin Type A in the Targeted Treatment of Disabling Tremor in Multiple Sclerosis

Sponsor: Eastern Health

Conditions Multiple Sclerosis Tremor

Interventions Botulinum Toxin Type A

Updated 5 times since 2017 Last updated: May 8, 2015 Started: Oct 31, 2008 Primary completion: Feb 28, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Multiple Sclerosis and Tremor and is currently completed. Eastern Health leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eastern Health
Melbourne Health

Data source: Melbourne Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia